key: cord-0694542-0041cay9 authors: Frontera, Jennifer A.; Boutajangout, Allal; Masurkar, Arjun V.; Betensky, Rebecca A.; Ge, Yulin; Vedvyas, Alok; Debure, Ludovic; Moreira, Andre; Lewis, Ariane; Huang, Joshua; Thawani, Sujata; Balcer, Laura; Galetta, Steven; Wisniewski, Thomas title: Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia date: 2022-01-13 journal: Alzheimers Dement DOI: 10.1002/alz.12556 sha: dc8f09074a03eb74465c03b205cda5a5813facfa doc_id: 694542 cord_uid: 0041cay9 INTRODUCTION: Neurological complications among hospitalized COVID‐19 patients may be associated with elevated neurodegenerative biomarkers. METHODS: Among hospitalized COVID‐19 patients without a history of dementia (N = 251), we compared serum total tau (t‐tau), phosphorylated tau‐181 (p‐tau181), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), ubiquitin carboxy‐terminal hydrolase L1 (UCHL1), and amyloid beta (Aβ40,42) between patients with or without encephalopathy, in‐hospital death versus survival, and discharge home versus other dispositions. COVID‐19 patient biomarker levels were also compared to non‐COVID cognitively normal, mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia controls (N = 161). RESULTS: Admission t‐tau, p‐tau181, GFAP, and NfL were significantly elevated in patients with encephalopathy and in those who died in‐hospital, while t‐tau, GFAP, and NfL were significantly lower in those discharged home. These markers correlated with severity of COVID illness. NfL, GFAP, and UCHL1 were higher in COVID patients than in non‐COVID controls with MCI or AD. DISCUSSION: Neurodegenerative biomarkers were elevated to levels observed in AD dementia and associated with encephalopathy and worse outcomes among hospitalized COVID‐19 patients. Neurological complications, particularly encephalopathy, are common among hospitalized COVID-19 patients, 1-3 and long-term cognitive abnormalities persist in nearly 50% of hospital survivors. 4 However, the mechanisms underpinning cognitive dysfunction in acute and postacute COVID-19 patients are not well understood. One possibility is that protracted hypoxia and the hyperinflammatory state encountered in acute, severe COVID-19 may lead to neuronal and glial cell injury, which could be measured in the blood using sensitive digital enzyme-linked immunosorbent assay or single molecule array technology (SIMOA). In this study, we hypothesized that blood biomarkers of neuronal and glial injury would be elevated in hospitalized COVID-19 patients with clinical evidence of new onset of cognitive dysfunction (specifically toxic-metabolic encephalopathy [TME]), and that elevated neurodegenerative biomarkers would be associated with a higher risk of in-hospital death and reduced rates of discharge home. We further aimed to compare neurodegenerative biomarker levels in hospitalized COVID patients to non-COVID controls with varying degrees of cognitive impairment (normal, mild cognitive impairment [MCI] , or Alzheimer's disease [AD] ) to gauge their degree of brain injury. We chose to assess neurofilament light chain (NfL), a cytoskeletal intermediate filament protein integral to axons in the central and peripheral nervous system, which has been noted to be elevated in patients with COVID-19, 5-10 as well as glial fibrillary acidic protein (GFAP), which is a specific indicator of glial/astrocyte injury, and ubiquitin carboxy-terminal hydrolase L1 (UCHL1) and total tau (t-tau), which are a neuron-specific proteins. Plasma t-tau, NfL, and GFAP have also been reported to be elevated in AD. [11] [12] [13] Additionally, we evaluated phosphorylated tau-181 (p-tau181), and amyloid beta (Aβ) 40 and 42, which are more specific biomarkers for AD-type pathology. 11, [14] [15] [16] Notably, UCHL1, 17, 18 GFAP, 19 tau, 19 and NfL 20, 21 are also elevated after blood-brain barrier (BBB) disruption, which has been documented in neuropathological studies of COVID-19 decedents 22 as well as in AD. We conducted a retrospective analysis of COVID-19 patients who were prospectively enrolled in the Study of Neurologic and Psychiatric Events in Acute COVID-19 (SNaP Acute COVID) study, 3 Blood inflammatory markers collected as part of clinical care during the hospital encounter were abstracted from the medical record including interleukin-6 (IL-6), C-reactive protein (CRP), D-dimer, and ferritin levels. The values obtained at hospital day 0 were used for analyses. Neurological diagnoses made during hospitalization (including TME, hypoxic-ischemic encephalopathy, stroke [ischemic or hemorrhagic], seizure, neuropathy, myopathy, movement disorder, encephalitis/meningitis, myelopathy, myelitis) followed established criteria and were coded for COVID-19 patients found to have a new neurological complication (excluding recrudescence or worsening of old neurological deficits) as diagnosed by in-hospital neurology teams. TME was coded for patients with new changes in mental status in the absence of focal neurological deficits (except in cases of hypo/hyperglycemia), clinical or electrographic seizures, or primary structural brain disease. For patients who had received sedating medications, an adequate washout (4-5 half-lives) was required for mental status assessment prior to diagnosis with TME. Etiologies of TME included: septic encephalopathy, uremia, hypoxia, hypercapnia, liver failure, electrolyte disturbances, hyper/hypothermia, thyroid dysfunction, nutritional deficiencies, environmental exposures, and acid/base abnormalities, among others. 1 Hypoxic-ischemic encephalopathy (HIE), a subcategory of TME, was defined as a global cerebral insult due to oxygen deprivation to the brain or lack of perfusion to the brain caused by systemic hypoxemia, hypotension, or cardiac arrest. 27 HIE was diagnosed among patients with new neurologic deficits and/or characteristic radiographic findings on head computed tomography or magnetic resonance imaging (MRI) scans. Patients with altered mental status due to another acute neurological diagnosis that could account for the observed exam findings (e.g., stroke, seizure, traumatic brain injury) 28 or abnormal mental status due to sedative medications were excluded from the TME diagnostic category. Subsidiary review of all neurological diagnoses was performed by relevant neurological subspecialists on the study team (e.g., stroke, neurocritical care, epilepsy subspecialists). Patients could be coded for more than one neurological complication. Demographic data, past medical history, clinical course, and hospital outcomes (mortality rates, discharge disposition, ventilator days, and hospital length of stay) were collected. Severity of illness during hospitalization was assessed using the worst recorded Sequential Organ Failure Assessment (SOFA) score. Past neurological history included: history of ischemic or hemorrhagic stroke, hydrocephalus, brain tumor, headache, seizure, traumatic brain injury, neuropathy, myasthenia gravis, multiple sclerosis, or movement disorder. The primary outcomes were serum levels of t-tau, p-tau181, NfL, GFAP, UCHL1, Aβ40, Aβ42, the ratio of Aβ42/Aβ40, and the ratio of p-tau181/Aβ42 compared between hospitalized COVID-19 patients who (1) developed TME versus those who did not, (2) died in-hospital or were discharged to hospice versus those who survived to discharge, and (3) were discharged home versus other discharge dispositions (in-hospital death/hospice, discharge to a nursing home, longterm acute care facility, acute or subacute rehabilitation facility). Secondary outcomes included the comparison of serum biomarker levels among COVID-19 patients to plasma biomarker levels of NfL, GFAP, and UCHL1 in non-COVID controls with normal cognition, MCI, or AD. This study was approved by the NYU Grossman School of Medicine Institutional Review Board. All patients or their surrogates provided consent for participation in blood banking. Based on the number of subjects in our sample for whom we were able to measure the biomarkers, we had approximately 80% power to detect (with a two-sided, 0.05 level t test) the following effect sizes (noted in Cohen d values, which reflect the difference between the two groups measured in standard deviations) for the biomarkers between those with TME compared to those without TME: d = 0.39 for NfL, UCHL1, GFAP (with 75 with TME and 176 without TME), d = 0.39 for total tau (73 with TME and 168 without TME), d = 0.50 for Aβ40 (47 with TME and 99 without TME), and d = 0.55 for Aβ42 (39 with TME and 81 without). The actual effect sizes in our data were comparable to these for NfL and UCHL1, but were lower for the other markers, indicating that we had lower power to detect differences in t-tau, p-tau181, When necessary, non-normally distributed dependent variables were transformed (e.g., log10 transformation). Correlations between biomarker levels and demographics, severity of illness measures, and inflammatory laboratory values were assessed using two-tailed Spearman's rank correlation coefficients. Using cause-specific multivariable Cox proportional hazard regression models, we fit the event times of (1) diagnosis of TME (2) A total of 302 patients from the SNaP Acute COVID cohort had banked serum specimens available for analysis. After excluding 51 patients Highest serum IL-6, pg/mL, median (IQR) 24(7-82) patients compared to MCI and normal subjects, and were similar to levels observed in AD subjects ( Figure 3 , Table S1 in supporting information). In this study, we identified significant elevations in blood biomarkers of neuronal and glial degeneration among hospitalized COVID-19 patients with clinical signs of neurological injury, specifically TME. Indeed, higher admission levels of neuronal degeneration markers p-tau181 and UCHL1 were significantly associated with TME, even after adjusting for age, sex, race, prior neurological disease, and severity of COVID-19 illness. Similarly, in multivariable analyses, elevations in total tau, NfL, and GFAP, in particular, were associated with reduced likelihood of discharge home. Furthermore, we found that levels of NfL, GFAP, and UCHL1 were as high as, or significantly higher than, N = 251) . NfL, GFAP, and UCHL1 levels were significantly higher in COVID patients compared to no cognitive impairment, and MCI patients; and NfL and GFAP were additionally significantly higher than AD patients, after adjusting for age and sex differences between groups. Abeta, amyloid beta; AD, Alzheimer's disease; GFAP, glial fibrillary acidic protein; MCI, mild cognitive impairment; NfL, neurofilament light chain; pTau , phosphorylated tau; UCHL1, ubiquitin carboxyl-terminal hydrolase isozyme L1 TA B L E 4 Multivariable Cox proportional hazard ratios among COVID-19 patients for each measured biomarker and the outcomes of Neurological events, toxic metabolic encephalopathy (TME), in-hospital death, and discharge home We found significant correlations between neurodegenerative biomarkers and the inflammatory marker D-dimer, which may provide some insight into mechanisms of acute brain injury after SARS-CoV- Aβ. 29 Hypoxia-induced tau phosphorylation with corresponding memory deficits has been documented in animal models exposed to hypoxia for 6 hours/day for 1 to 8 weeks 30 and elevations of inflammatory cytokines such as IL-6 and IL-1 correlate with cognitive dysfunction and the promotion of amyloid plaque and neurofibrillary tangle pathology in animal models. 31 We have previously found that COVID-19related TME is significantly associated with elevations in inflammatory markers, including IL-6, D-dimer, CRP, and ferritin. 3 been implicated in AD-type pathology among non-COVID patients. 37 Finally, another important association between COVID-19 and AD is the linkage to the apolipoprotein E ε4 genotype, which is both a marker for increased COVID-19 severity, 38, 39 and the most impactful genetic risk factor for late-onset AD. 40 We did not, however, identify correlates with blood Aβ40 or Aβ42 levels, which may reflect the fact that we were underpowered to detect differences in amyloid biomarkers, or be related to the use of serum (rather than plasma) for these measurements, which is known to increase variability. 25 Elevations in blood and CSF NfL, GFAP, and t-tau among COVID-19 patients have been described by others, and in some cases, compared to normal control groups. [5] [6] [7] 9, 10, [41] [42] [43] [44] [45] However, none of these studies explicitly excluded COVID-19 patients with a baseline history of dementia or cognitive decline, which likely would confound results. Additionally, NfL is not specific to the central nervous system (CNS) and can be elevated in the context of peripheral neuropathy, [46] [47] [48] including COVID-related critical illness neuropathy/myopathy 8 and Guillain-Barre Syndrome. 48 Similarly, elevated GFAP has been reported in COVID-19 patients with critical illness neuropathy/myopathy and levels correlate with nerve amplitudes. 8 More AD-specific biomarkers, such as p-tau181 have not previously been explored in COVID-19 patients. In neuropathological studies of plasma p-tau181 and NfL, both biomarkers accurately distinguish pathology-confirmed AD from healthy controls, but only p-tau181 distinguished AD from non-AD dementia cases and showed specificity for neuritic plaque pathology and Braak stage. 15, 49 Similarly, p-tau181 levels escalate progressively with worsening CDR scores and correlate with multiple cognitive domains, while NfL, t-tau, and Aβ levels do not perform as well. 16, 50 In non-COVID patients, increases in CSF and plasma biomarkers of t-tau, p-tau, and NfL (comparing pre-operative to post-operative levels) have been found to correlate with the incidence and severity of delirium in patients undergoing surgery. [51] [52] [53] [54] Furthermore, elevations in NfL have been associated with worse cognitive and functional outcomes in post-operative patients and patients with septic encephalopathy. 54,55 A large meta-analysis of non-COVID survivors of critical illness has also identified associations of delirium with Aβ40, IL-6, and IL-1R antagonist. 56 Our study is unique in that we identified elevations across a spectrum of CNS specific markers, including neuronal (t-tau, UCHL1), and astrocytic/glial markers (GFAP), as well as AD-related markers (p-tau181). There are limitations to this study. First, though we excluded patients with a history of dementia or cognitive decline, it is possible that some COVID-19 patients may have had preclinical or undiagnosed cognitive impairment. Second, biomarkers were only measured at one time point and we do not have data on trajectories of these markers. Some studies have identified persistent elevations in blood NfL levels for 30 to 50 days in small COVID-19 cohorts, 9, 42 while GFAP levels may initially spike and then decline after the acute phase of infection. 42 The association of these biomarkers with formal cognitive testing after the acute phase of COVID-19 has not been demonstrated and is an active area of research needed to unravel the long-term cognitive implications of elevated neurodegenerative biomarkers. Third, we did not have inflammatory marker data (e.g., IL-6, CRP, D-dimer, fibrinogen) in control patients. Fourth, due to limited sample availability, fewer specimens were available for p-tau181, Aβ40, or Aβ42 analysis, which may have limited our ability to detect important differences among these biomarkers. Last, we compared serum biomarkers in COVID-19 patients to plasma levels in non-COVID controls, because pre-COVID banked serum specimens were not available in controls. Though NfL, GFAP, and UCHL1 levels are equivalent in serum and plasma, 25 we were unable to compare t-tau, p-tau181, or Aβ levels to controls due to differences in specimen type. 25, 26 Additionally, we did not have cerebrospinal fluid specimens available for biomarker analysis, which may have provided a more accurate assessment of the cerebral milieu. Serum neuronal, glial, and axonal neurodegenerative biomarkers, including t-tau, p-tau181, UCHL1, GFAP, and NfL were significantly elevated in patients with encephalopathy and worse discharge disposition after hospitalization for COVID-19. These markers correlated with the severity of COVID illness. Furthermore, levels of NfL, GFAP, and UCHL1 in hospitalized COVID patients were similar to, or higher than, levels observed in non-COVID AD dementia patients. Additional studies tracking trajectories of these biomarkers over time and their association with long-term cognitive outcomes among COVID-19 survivors are warranted. The authors would like to thank the patients and families who participated in this study. This study was funded by a grant from the NIH/NIA (PI: Wisniewski) COVID-19 administrative supplement 3P30AG066512-01. Toxic metabolic encephalopathy in hospitalized patients with COVID-19 Neurological symptoms and complications in predominantly hospitalized COVID-19 patients: Results of the European multinational LEOSS registry A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19 Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19 Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: a prospective study Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19 Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease Estimation of Tau and phosphorylated Tau181 in serum of Alzheimer's disease and mild cognitive impairment patients Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer's disease. Brain Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease Elevated serum ubiquitin carboxyterminal hydrolase L1 is associated with abnormal blood-brain barrier function after traumatic brain injury Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases Increases of plasma levels of glial fibrillary acidic protein, Tau, and amyloid beta up to 90 days after traumatic brain injury Longitudinal performance of plasma neurofilament light and Tau in professional fighters: the Professional Fighters Brain Health Study Neurofilament light chain level in traumatic brain injury: a system review and meta-analysis Microvascular injury in the brains of patients with Covid-19 The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Neuro biomarker levels measured with high-sensitivity digital ELISA differ between serum and plasma Hypoxic-ischemic brain injury: pathophysiology, neuropathology and mechanisms Metabolic encephalopathies in the critical care unit. Continuum (Minneap Minn) What are the links between hypoxia and Alzheimer's disease? Hypoxia-induced tau phosphorylation and memory deficit in rats Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection Intracerebral endotheliitis and microbleeds are neuropathological features of COVID-19 Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a postmortem study Neuropathologic findings of patients with COVID-19: a systematic review COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital Inflammation as a central mechanism in Alzheimer's disease APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort Residence, clinical features, and genetic risk factors associated with symptoms of COVID-19 in a cohort of older people in Madrid Future horizons in Alzheimer's disease research CSF biomarkers in patients with COVID-19 and neurologic symptoms: a case series Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19 SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19 Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease Serum neurofilament light chain predicts long-term prognosis in Guillain-Barre syndrome patients Alzheimer's Disease Neuroimaging Initiative Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease Cohort Analysis of the Association of Delirium Severity with Cerebrospinal Fluid Amyloid-Tau-Neurodegeneration Pathologies Association between plasma tau and postoperative delirium incidence and severity: a prospective observational study A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients Association of Plasma Neurofilament Light with Postoperative Delirium The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy -A prospective, pilot observational study Meta-analysis of ICU Delirium Biomarkers and Their Alignment With the NIA-AA Research Framework Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia. Alzheimer's Dement Betensky services on safety monitoring boards of Apotex, Reata, Biogen, PTI, and Alexion, as well as being an advisor to Alexion, Apotex, Reata, Biogen, and PTI. Dr. Betensky has given seminar at the University of Vigo.